Article info

Download PDFPDF

What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France

Authors

  1. Correspondence to Dr Claire Paquet; claire.paquet{at}inserm.fr
View Full Text

Citation

Cognat E, Mouton Liger F, Troussière A on behalf of ePLM network, et al
What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France

Publication history

  • Received August 31, 2018
  • Revised March 19, 2019
  • Accepted April 8, 2019
  • First published May 30, 2019.
Online issue publication 
May 30, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.